Molecular PCR UTI Test + ABR

Urinary Tract Infection Panel

Promus Diagnostics’ comprehensive molecular UTI panel provides a complete set of data much faster than traditional urine culture — making results more relevant, meaningful and reliable.

Urinary Tract Infection
+ Antibiotic Resistance Genes (UTI+ABR)

Promus Diagnostics Molecular PCR UTI Test is the Solution

Urinary Tract Infections (UTI) are the most common bacterial infection among long term care residents and the second most common infection diagnosed in the acute hospital setting. UTIs account for almost 5% of all emergency department visits by adults aged 65 years and older in the United States each year.

Traditional testing for a UTI involves a urine culture which can take days to complete, greatly reducing sensitivity and accuracy. Without an accurate identification of the pathogen, healthcare providers may treat the patient with a course of antibiotics that may not be the optimal choice based on pathogens present resulting in persistent or recurring UTIs.

A recent study by Washington University found that of the 670,450 women tested, 46.7% “received antibiotic prescriptions for inappropriate agents” and 76.1% received antibiotics for an incorrect duration.1

At Promus Diagnostics we provide a better solution for identifying the pathogens causing an UTI using real-time PCR technology. Our UTI+ABR test panel can quickly and accurately identify 31 different infection causing pathogens and 22 antimicrobial resistance markers, giving healthcare providers the clearest and most robust information to develop a treatment regimen.

Improper diagnosis or ineffective treatment plan for a UTI could cause
  • Permanent kidney damage
  • Life-threatening sepsis
  • Ongoing discomfort
  • Chronic infections

“Antibiotic stewardship is the effort to measure and improve how antibiotics are prescribed by clinicians and used by patients.”2

About the UTI-ABR PCR Panel

Promus Diagnostics’ UTI+ABR panel is a semi-quantitative real-time PCR test designed to detect 31 clinically significant pathogens as causative agents of urinary tract infections and 22 antimicrobial resistance markers. Our comprehensive test provides clinicians with reliable and clear results so they can more effectively treat patients with UTIs or address recurring infections.

PCR (Polymerase Chain Reaction) is a molecular testing technology that detects specific DNA strand targets with the sensitivity to accurately and reliably identify pathogens that would be difficult to grow in standard cultures. Our PCR panel for UTI detects a complete range of pathogens including bacteria, fungi, polymicrobial infections, and antimicrobial resistance markers.

Promus Diagnostics specializes in molecular diagnostic testing for infectious diseases using state-of-the-art scientific equipment from the most renowned biotechnology companies. UTI screening is an area of focus for Promus Diagnostics because we believe to achieve true antibiotic stewardship, healthcare providers need to have infection-based treatment guidance they can trust.

0
Clinically Significant Pathogens
0
Antimicrobial Resistance Markers

Identification where culture or dipstick may not have detected infection, or inconclusive due to sample contamination

Reduce or eliminate recurrent infections based on superior identification of Uropathogens for proper treatment

Informed drug selection to remediate infection, decrease incidents of adverse events as well as lessen the potential for antibiotic resistance

PCR vs. Traditional Culture

Molecular PCR Testing

  • Results within hours of starting the test
  • Diagnosis based on the detection of specific DNA strand targets
  • Detects polymicrobial infections
  • Not dependent on pathogen volume in the sample
  • Identified antimicrobial resistance markers

Traditional Culture Screening

  • Culture can take multiple days for growth to occur
  • Diagnosis based analysis under a microscope
  • Useful for infections caused by single bacteria
  • Low pathogen counts may lead to low growth and a false-negative result
  • Unable to identify resistance markets

Solutions for Long Term Care Facilities

Provide your patients the quickest and most accurate diagnosis possible.

  • 24 hour turn-around time from the time the lab receives the sample
  • Significantly reduces the chances of receiving “contaminated” results
  • Provides infection based treatment guidance
  • Improves antibiotic stewardship
  • Enhances the ability to appropriately assess and manage UTIs.
  • Reduces progression of infection & healthcare costs
Contact Business Services

Target Pathogens

  • Acinetobacter baumannii
  • Actinobaculum schaalii
  • Aerococcus urinae
  • Candida albicans
  • Candida auris
  • Candida glabrata
  • Candida parapsilosis
  • Citrobacter freundii
  • Citrobacter koseri
  • Coagulase Negative Staph
  • Corynebacterium riegelii
  • Enterobacter aerogenes
  • Enterobacter cloacae
  • Enterococcus faecalis
  • Enterococcus faecium
  • Escherichia coli
  • Klebsiella oxytoca
  • Klebsiella pneumoniae
  • Morganella morganii
  • Mycoplasma hominis
  • Pantoea agglomerans
  • Proteus mirabilis
  • Proteus vulgaris
  • Providencia stuartii
  • Pseudomonas aeruginosa
  • Serratia marcescens
  • Staphylococcus aureus
  • Streptococcus agalactiae
  • Ureaplasma urealyticum
  • Viridans Group Strep

ABR Detection (Classifications)

  • Beta-lactam cephalosporin
  • Beta-lactam carbapenem
  • Beta-lactam methicillin
  • Quinolone
  • Glycopeptide vancomycin
  • Trimethoprim
  • Sulfonamide
  • Nitrofuratoin